FTC, FDA to enhance antitrust oversight in biologics market

Biotech

The Federal Trade Commission and Food and Drug Administration have signaled they will be increasing their oversight of any potential antitrust behavior in the biologics market.

THIS IS MEMBERS-ONLY CONTENT

SINGLE MEMBERSHIP                                             CORPORATE MEMBERSHIP

You are not logged in and do not have access to members-only content.

If you are already a registered user or a member, SIGN IN now.